

## CURRICULUM VITAE



---

### BIOGRAPHICAL

Name: Yüksel Peker

---

### EDUCATION and TRAINING

#### UNDERGRADUATE:

<i>Dates Attended</i>	<i>Name and Location of Institution</i>	<i>Degree Received and Year</i>	<i>Major Subject</i>
N/A	N/A	N/A	N/A

#### GRADUATE:

<i>Dates Attended</i>	<i>Name and Location of Institution</i>	<i>Degree Received and Year</i>	<i>Major Subject</i>
1979-1985	Medical Faculty, University of Istanbul, Istanbul, Turkey	M.D. 1985-Sept-30	Medicine

#### POSTGRADUATE:

<i>Dates Attended</i>	<i>Name and Location of Institution</i>	<i>Degree Received and Year</i>	<i>Major Subject</i>
1989-1991	Clinical Practice (Residency), Internal Medicine, General Surgery, Psychiatry, and General Practice, Skaraborg Hospital, Skövde, Sweden	Licensed Physician 1991	Medicine
1991-1996	Internship and Training for Internal Medicine, Skaraborg Hospital,	Specialist 1996	Internal Medicine

1996-1998	Skövde, Sweden Internship and Training for Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden	Specialist 1998	Pulmonary Medicine
-----------	---	--------------------	--------------------

---

**APPOINTMENTS and POSITIONS**

**ACADEMIC:**

<i>Years Inclusive</i>	<i>Name and Location of Institution or Organization</i>	<i>Rank/Title</i>
2000	Dept. of Pulmonary Medicine Faculty of Medicine, University of Gothenburg, Sweden	Ph. D.
2007-2015	Dept. of Pulmonary Medicine Faculty of Medicine, University of Gothenburg, Sweden	Associate Professor
2011-2015	Dept. of Molecular and Clinical Medicine/Cardiology Faculty of Medicine, University of Gothenburg, Sweden	Adjunct Lecturer
2015-2017 Lecturer	Dept. of Molecular and Clinical Medicine/Cardiology Faculty of Medicine, University of Gothenburg, Sweden	Visiting Senior
2015-ongoing	Dept. of Pulmonary Medicine Faculty of Medicine, Marmara University, Istanbul, Turkey	Professor
2017-ongoing Professor	Dept. of Medicine, School of Medicine  University of Pittsburg, USA	Adjunct

---

**CERTIFICATION and LICENSURE**

**SPECIALTY CERTIFICATION:** Internal Medicine

<b><i>Certifying Board:</i></b> The Swedish National Board of Health and Welfare 1996	<b><i>Year</i></b>
---	--------------------

**SPECIALTY CERTIFICATION:** Pulmonary Medicine

<b><i>Certifying Board:</i></b> The Swedish National Board of Health and Welfare 1998	<b><i>Year</i></b>
---	--------------------

**MEDICAL or OTHER PROFESSIONAL LICENSURE:** Medical Doctor

<b><i>Licensing Board/State</i></b> Medical Faculty, University of Istanbul, Turkey	<b><i>Year</i></b> 1985
--	----------------------------

**MEDICAL or OTHER PROFESSIONAL LICENSURE:** Licensed Medical Doctor  
**Licensing Board/State** **Year**  
 The Swedish National Board of Health and Welfare  
 1991

**MEDICAL or OTHER PROFESSIONAL LICENSURE:** Accredited Sleep Medicine Specialist  
**Licensing Board/State** **Year**  
 Nordic Association of Sleep Research & Sleep Medicine Societies 2009

---

**MEMBERSHIP in PROFESSIONAL and SCIENTIFIC SOCIETIES**

<b>Organization</b>	<b>Year</b>
American Thoracic Society	1998-ongoing
European Respiratory Society	1998-ongoing
European Sleep Research Society	1998-ongoing
Swedish Sleep Medicine and Sleep Research Society	1996-ongoing
Swedish Lung Medicine Association	1998-ongoing
Turkish Thoracic Society	2015-ongoing
Turkish Sleep Medicine Society	2015-ongoing

---

**HONORS**

<b>Title of Award</b>	<b>Year</b>
-----------------------	-------------

---

**PUBLICATIONS**

**1. Refereed articles**

1. Luyster FS, Strollo PJ Jr, Thunström E, **Peker Y**. Long-term use of continuous positive airway pressure therapy in coronary artery disease patients with nonsleepy obstructive sleep apnea. *Clin Cardiol* 2017 Dec 14. doi: 10.1002/clc.22827. [Epub ahead of print]
2. **Peker Y**, Glantz H, Thunström E, Wegscheider K, Eulenburg C. Outcomes in Coronary Artery Disease Patients with Sleepy Obstructive Sleep Apnoea on CPAP. *Eur Resp J* 2017 Dec 7;50(6). pii: 1700749. doi: 10.1183/13993003.00749-2017. Print 2017 Dec.
3. Thunström E, Glantz H, Yucel-Lindberg T, Lindberg K, Saygin M, **Peker Y**. CPAP does not reduce inflammatory biomarkers in patients with coronary artery disease and nonsleepy obstructive sleep apnea: a randomized controlled trial. *Sleep* 2017 Nov 1;40(11). doi: 10.1093/sleep/zsx157.
4. Saygin M, Ozguner MF, Onder O, Doguc DK, Ilhan I, **Peker Y**. The impact of sleep deprivation on hippocampal-mediated learning and memory in rats. *Bratisl Lek Listy* 2017; 118: 408-416
5. Glantz H, Johansson MC, Thunstrom E, Wallentin Guron C, Uzel H, Saygin M, Herlitz J, **Peker Y**. Effect of CPAP on diastolic function in coronary artery disease patients with nonsleepy obstructive sleep apnea: A randomized controlled trial. *Int J Cardiol* 2017; 241:12-18.
6. Saraç S, Afşar GÇ, Oruç Ö, Topçuoğlu ÖB, Saltürk C, **Peker Y**. Impact of Patient Education on Compliance with Positive Airway Pressure Treatment in Obstructive Sleep Apnea. *Med Sci Monit* 2017; 23: 1792-1799.

7. Thunström E, Manhem K, Yucel-Lindberg T, Rosengren A, Lindberg C, **Peker Y**. Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial. *Ann Am Thorac Soc* 2016; 13: 2002-2011.
8. Veje M, Nolskog P, Petzold M, Bergström T, Lindén T, **Peker Y**, Studahl M. Tick-Borne Encephalitis sequelae at long-term follow-up: a self-reported case-control study. *Acta Neurol Scand* 2016; 134: 434-441.
9. **Peker Y**, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunström E. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Non-Sleepy Obstructive Sleep Apnea: The RICCADSA Randomized Controlled Trial. *Am J Respir Crit Care Med* 2016; 194: 613-620.
10. Thunström E, Manhem K, Rosengren A, **Peker Y**. Blood Pressure Response to Losartan and Continuous Positive Airway Pressure in Hypertension and Obstructive Sleep Apnea. *Am J Respir Crit Care Med* 2016; 193: 310-320.
11. Demir A, Ardic S, Firat H, Karadeniz D, Aksu M, Ucar ZZ, Sevim S, Ozgen F, Yilmaz H, Itil O, **Peker Y**, Aygul F, Kiran S, Gelbal S, Cepni Z, Akozer M, for the TAPES Investigation Committee. Prevalence of sleep disorders in the Turkish adult population epidemiology of sleep study. *Sleep and Biological Rhythms* 2015; 13: 298-308.
12. Thunström E, Glantz H, Fu M, Yucel-Lindberg, Petzold M, Lindberg K, **Peker Y**. Increased inflammatory activity in nonobese patients with coronary artery disease and obstructive sleep apnea. *Sleep* 2015; 38:463-471.
13. Glantz H, Thunström E, Johansson MC, Wallentin Guron C, Uzel H, Ejdebäck J, Nasic S, **Peker Y**. Obstructive sleep apnea is independently associated with worse diastolic function in coronary artery disease. *Sleep Med* 2015; 16:160-167.
14. Cetin S, Oztürk MA, Barındık N, Imren E, **Peker Y**. Increased coronary intervention rate among diabetic patients with poor glycaemic control: A cross-sectional study. *Bosn J Basic Med Sci* 2014;14:16-20.
15. Glantz H, Thunstrom E, Herlitz J, Cederin B, Nasic S, Ejdeback J, **Peker Y**. Occurrence and predictors of obstructive sleep apnea in a revascularized coronary artery disease cohort. *Ann Am Thorac Soc* 2013; 10: 350-356.
16. Hoever P, Dorffner G, Beneš H, Penzel T, Danker-Hopfe H, Barbanøj MJ, Pillar G, Saletu B, Polo O, Kunz D, Zeitlhofer J, Berg S, Partinen M, Bassetti CL, Högl B, Ebrahim IO, Holsboer-Trachsler E, Bengtsson H, **Peker Y**, Hemmeter UM, Chiossi E, Hajak G, Dingemanse J. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. *Clin Pharmacol Ther* 2012; 91: 975-985.
17. Cilli A, Batmaz F, Demir I, Boz A, Toprak E, Ozdemir T, **Peker Y**. The diagnostic yield of exercise stress testing as a screening tool for subclinical coronary artery disease in patients with moderate to severe obstructive sleep apnea *J Clin Sleep Med* 2011; 7: 25-29.
18. Ismailogullari S, Korkmaz C, **Peker Y**, Bayram F, Karaca Z, Aksu M. Impact of long-term gonadotroping replacement treatment on sleep in men with idiopathic hypogonadotropic hypogonadism. *J Sex Med* 2011; 8: 2090-2097.
19. Celen YT, Hedner J, Carlson J, **Peker Y**. Impact of gender on incident diabetes in obstructive sleep apnea: a 16-year follow-up. *J Clin Sleep Med* 2010; 6: 244-250.
20. Karimi M, Koranyi J, Franco C, **Peker Y**, Eder DN, Angelhed JE, Lönn L, Grote J, Bengtsson BÅ, Svensson J, Hedner J, Johannsson G. Increased neck soft tissue mass and worsening of

obstructive sleep apnea after growth hormone treatment in men with abdominal obesity. *J Clin Sleep Med* 2010; 6: 256-263.

21. Bayram NA, Ciftci B, Keles T, Durmaz T, Turhan S, Bozkurt E, **Peker Y**. Endothelial function in normotensive men with obstructive sleep apnea before and six months after CPAP treatment *SLEEP* 2009; 32:1257-1263.
22. Aksu K, Firat-Guven S, Aksu F, Ciftci B, Ulukavak-Ciftci T, Aksaray S, Sipit T, **Peker Y**. Obstructive sleep apnoea, cigarette smoking and plasma orexin-A in a sleep clinic cohort. *J Int Med Res* 2009; 37: 331-340.
23. **Peker Y**, Glantz H, Thunström E, Kallryd A, Herlitz J, Ejdebäck J. Rationale and design of the Randomized Intervention with Cpap in Coronary Artery Disease and Sleep Apnoea (RICCADSA) trial. *Scand Cardiovasc J* 2009; 43:24-31.
24. Acarturk G, Unlu M, Yuksel S, Albayrak R, Koken T, **Peker Y**. Obstructive sleep apnoea, glucose tolerance and liver steatosis in obese women. *J Int Med Res* 2007; 35: 458-466.
25. Kirbas G, Abakay A, Topcu F, Kaplan A, Unlu M, **Peker Y**. Obstructive sleep apnoea, cigarette smoking and serum testosterone levels in a male sleep clinic cohort. *J Int Med Res* 2007; 35: 38-45.
26. Johansson MC, Eriksson P, **Peker Y**, Hedner J, Råstam L, Lindblad U. The influence of patent foramen ovale on oxygen desaturation in obstructive sleep apnea. *Eur Respir J* 2007; 29:149-155.
27. **Peker Y**, Carlson J, Hedner J. Increased incidence of coronary artery disease in sleep apnoea: A long-term follow-up. *Eur Respir J* 2006; 28:596-602.
28. **Peker Y**, Svensson J, Hedner J, Grote L, Johannsson G. Sleep apnea and quality of life in growth hormone deficient adults before and after six months of growth hormone replacement therapy. *Clin Endocrin* 2006; 65:98-105.
29. Hedner J, Bengtsson-Boström K, **Peker Y**, Grote L, Råstam L, Lindblad U. Hypertension prevalence in OSA and gender: a population-based case-control study. *Eur Respir J* 2006; 27: 564-570.
30. Ding Z, Grote L, **Peker Y**, Lindblad U, Hedner J. Validation a portable monitoring device for sleep apnea diagnosis in a population-based cohort using synchronized home polysomnography. *SLEEP* 2006; 29: 367-374.
31. Torvaldsson S, Grote L, **Peker Y**, Basun H, Hedner J. A randomized placebo-controlled trial of an NMDA receptor antagonist in sleep disordered breathing. *J Sleep Res* 2005; 14: 149-155.
32. Ding Z, Grote L, Eder DN, **Peker Y**, Hedner J. Obstructive apneic events induce alpha-receptor mediated digital vasoconstriction. *SLEEP* 2004; 27: 485-489.
33. Hedner J, Kraiczi H, **Peker Y**, Murphy P. Reduction of sleep disordered breathing following physostigmine. *Am J Respir Crit Care Med* 2003; 168: 1246-1251.
34. **Peker Y**, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: A 7-year follow-up. *Am J Respir Crit Care Med* 2002; 166: 159-165.
35. Kraiczi H., Caidahl K, Samuelsson A, **Peker Y**, Hedner J. 2001. Impairment of vascular endothelial function and left ventricular filling: association with the severity of apnea-induced hypoxemia during sleep. *Chest* 2001; 119:1085-1091.
36. Kraiczi H, **Peker Y**, Caidahl K, Samuelsson A, Hedner J. Blood pressure, cardiac structure and severity of obstructive sleep apnea in a sleep clinic population. *Journal of Hypertension* 2001; 19: 2071-2078.

37. **Peker Y**, Hedner J, Kraiczi H, Löth S. Respiratory Disturbance Index: An independent predictor of mortality in coronary artery disease. *Am J Respir Crit Care Med* 2000; 162: 81-86.
38. Kraiczi H, Hedner J, **Peker Y**, Grote L. Comparison of Atenolol, Amlodipine, Enalapril, Hydrochlorothiazide and Losartan for antihypertensive treatment in patients with obstructive sleep apnea. *Am J Respir Crit Care Med* 2000; 161: 1423-1428.
39. Kraiczi H, Hedner J, **Peker Y**, Carlson J. Increased vasoconstrictor sensitivity in obstructive sleep apnea. *J Appl Physiol* 2000; 89: 493-498.
40. **Peker Y**, Kraiczi H, Hedner J, Löth S, Johansson Å, Bende M. An independent association between obstructive sleep apnoea and coronary artery disease. *Eur Respir J* 1999; 14: 179-184.
41. **Peker Y**, Hedner H, Johansson Å, Bende M. Reduced hospitalization due to cardiovascular and pulmonary disease in patients with obstructive sleep apnea on nasal CPAP treatment. *SLEEP* 1997; 20: 577-584.

## 2. Reviews

42. **Peker Y**. Obstructive sleep apnea and driving risk: The current Turkish legislation, controversies, and future perspectives. *Marmara Medical Journal* 2016; 29: 10-15.
43. **Peker Y**, Redline S. Update in sleep medicine in 2013. *Am J Respir Crit Care Med* 2014; 189: 1345-1350.
44. Celen YT, **Peker Y**. Cardiovascular consequences of sleep apnea – III : Impact of CPAP treatment. *Anadolu Kardiyol Derg* 2010; 10: 274-280.
45. Celen YT, **Peker Y**. Cardiovascular consequences of sleep apnea – II : Cardiovascular mechanisms. *Anadolu Kardiyol Derg* 2010; 10: 168-175.
46. Celen YT, **Peker Y**. Cardiovascular consequences of sleep apnea – I : Epidemiology. *Anadolu Kardiyol Derg* 2010; 10: 75-80.
47. Hedner J, Franklin K, **Peker Y**. Obstructive sleep apnea and coronary artery disease. *Sleep Medicine Clinics* 2007; 2: 559-564.
48. **Peker Y**, Grote L, Kraiczi H, Hedner J. Cardiovascular morbidity in obstructive sleep apnea (*Läkartidningen –review in Swedish-* 2002; 99: 4473-4479).

## Invited published papers (editorials/letters)

49. **Peker Y**, Strollo PJ Jr. A meta-analysis of positive airway pressure treatment for cardiovascular prevention: why mix apples and pears? *Evid Based Med* 2017; 22: 218-219.
50. **Peker Y**, Wegscheider K, Eulenburg C. Reply to Effect of CPAP Therapy on the Cardiovascular Outcomes in Patients with Nonsleepy Obstructive Sleep Apnea. *Am J Respir Crit Care Med* 2017; 196:662-663.
51. **Peker Y**, Strollo PJ Jr. CPAP did not reduce cardiovascular events in patients with coronary or cerebrovascular disease and moderate to severe obstructive sleep apnoea. *Evid Based Med* 2017; 22: 67-68.
52. **Peker Y**. REM-sleep: A nightmare for patients with obstructive sleep apnea? *Am J Respir Crit Care Med* 2014; 190: 1088-1090.
53. **Peker Y**. Growing research evidence for continuous positive airway pressure treatment for sleepy patients with milder obstructive sleep apnea. *Am J Respir Crit Care Med* 2012; 186: 583-584.
54. **Peker Y**. Platelet activity and cardiovascular risk in obesity and obstructive sleep apnea: compelling need for interdisciplinary research? *J Clin Sleep Med* 2011; 7: 179-180.

### Book chapters

55. **Peker Y**, Franklin K, Hedner J. Coronary artery disease and sleep apnea. In: Kryger MH, Roth TT, Dement WT (editors). *Principals and practice of sleep medicine*. 6th edition 2017. Elsevier Inc. Philadelphia, PA. 1264-1270.
56. Celen YT, **Peker Y**. Obstruktif uyku apne sonuçları (Turkish). In: Itil, Köktürk, Ardiç, Çudaraoğlu, Fırat (editors). *Uykuda Solunum Bozuklukları*. 2015. Türk Toraks Derneği Kitapları. Istanbul, Turkey. 311-342.
57. Bartnik M, **Peker Y**. Diabetes mellitus and obstructive sleep apnoea. In: Preedy, Patel, Le (editors). *Handbook of nutrition, diet and sleep*. 2013. Wageningen Academic Publishers, The Netherlands. 295-308.
58. Hedner J, Franklin K, **Peker Y**. Coronary artery disease and sleep apnea. In: Kryger, Roth, Dement (editors). *Principals and practice of sleep medicine*. 5th edition. 2011. Elsevier Inc, Philadelphia, PA. 1393-1399.
59. Celen YT, **Peker Y**. Obstruktif apnede kardiyovasküler hastalıklar (Turkish). In: Özlü, Metintas, Karadag, Kaya (editors). *Solunum sistemi ve hastaliklari*. 2010. Istanbul Medical Yayıncılık, Istanbul, Turkey. 2155-2174.
60. Hedner J, Franklin K, **Peker Y**. Coronary artery disease and sleep apnea. In: Kryger, Roth, Dement (editors). *Principals and practice of sleep medicine*. 4th edition. 2005. Elsevier Inc, Philadelphia, PA. 1203-1207.

### 3. Published abstracts

1. **Peker Y**, Glantz H, E Thunström, Guron C, Uzel H, Saygın M, Herlitz J, Johansson M. Effect of positive airway pressure on diastolic function in coronary artery disease patients with non-sleepy obstructive sleep apnea (5 September 2016). European Respiratory Society Meeting. London, England. *Eur Respir J 2013, Vol xx, Suppl xx, p.xxx*.
2. **Peker Y**, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunström E. Impact of continuous positive airway pressure on cardiovascular outcomes in coronary artery disease and obstructive sleep apnea: the RICCADSA trial. *Am J Respir Crit Care Med 2015, Vol 191, A6317*.
3. **Peker Y**, Thunström E, Glantz H, Fu Michael, Yücel-Lindberg T, Petzold M, Lindberg K. Obstructive sleep apnoea and increased inflammatory activity in nonobese patients with coronary artery disease in the RICCADSA trial (oral presentation). *European Respiratory Society Congress, Sept 18-22, 2013, Barcelona, Spain. Eur Respir J 2013, Vol xx, Suppl xx, p.xxx*.
4. Thunström E, Glantz H, Fu Michael, Yücel-Lindberg T, Petzold M, Lindberg K, **Peker Y**. Independent association between obstructive sleep apnea and increased inflammatory activity in nonobese patients with coronary artery (poster). *Svenskt kardiovaskulärt vårmöte, May 17-19, 2013, Gothenburg*.
5. **Peker Y**, Turgut-Celen Y, Stålkranz A, Sengören-Dikis Ö, Glantz H, Cederin B, Korkmaz S, Thunström E. One-year adherence to CPAP treatment in cardiac patients with nonsleepy sleep apnoea in the RICCADSA trial (poster). *European Respiratory Society Congress, Sept 1-5, 2012, Vienna, Austria. Eur Respir J 2012, Vol 40, Suppl 56, p.xxx*.
6. **Peker Y**, Glantz H, Thunström E, Cederin B, Herlitz J, Ejdebäck J. Cardiac function in a revascularized coronary artery disease with obstructive sleep apnoea with and without

- daytime sleepiness in the RICCADSA trial (oral presentation). *European Respiratory Society Congress, Sept 24-28, 2011, Amsterdam, Holland, Eur Respir J 2011, Vol xx, Suppl xx, p.xxx.*
7. **Peker Y**, Glantz H, Thunström E, Cederin B, Kallryd A, Ejdebäck J, Herlitz J. Rationale and design of the randomized intervention with CPAP in coronary artery disease and obstructive sleep apnea – the RICCADSA trial (poster). *APSS meeting, Minneapolis, Minnesota, June 11-15, 2011. SLEEP (Supplement) 2011, Vol 34, p. A236.*
  8. Glantz H, Thunström E, Cederin B, Kallryd A, Ejdebäck J, Herlitz J, **Peker Y**. Cardiac function at baseline in a revascularized coronary artery disease cohort with obstructive sleep apnea in the RICCADSA trial (poster). *Heart Failure Association of the European Cardiology Society, Heart Failure 2011, May 21-24, 2011, Gothenburg, Sweden*
  9. Glantz H, Thunström E, Cederin B, Kallryd A, Ejdebäck J, Herlitz J, **Peker Y**. Hjärtfunktion i RICCADSA kohorten med sömnapné (poster) (In Swedish). *Sv Läk, Riksst., 2010, Gothenburg.*
  10. Glantz H, Thunström E, Cederin B, Kallryd A, Ejdebäck J, Herlitz J, **Peker Y**. Obstructive sleep apnea and adherence to CPAP in coronary artery disease without daytime sleepiness: The RICCADSA trial (poster). *Svenskt kardiologiskt vårmöte, 2010, Gothenburg.*
  11. **Peker Y**, Glantz H, Thunström E, Cederin B, Kallryd A, Ejdebäck J, Herlitz J. Baseline characteristics of the revascularized patients with coronary artery disease and obstructive sleep apnoea in the RICCADSA trial (oral presentation). *European Respiratory Society Congress, Sept 18-22, 2010, Barcelona, Spain. Eur Respir J 2010, Vol 36, Suppl 54, p.xxx.*
  12. Thunström E, Glantz H, Cederin B, Kallryd A, Ejdebäck J, Herlitz J, **Peker Y**. Kliniska karaktäristika av revasculariserade kranskärlssjuka i RICCADSA studien: Sömnapné vanligare än obesitas, rökning, diabetes och hypertoni (In Swedish) (award for best oral presentation) *Sv Läk, Riksst., 2010, Gothenburg.*
  13. Glantz H, Thunström E, Cederin B, Kallryd A, Ejdebäck J, Herlitz J, **Peker Y**. Cardiac function in the RICCADSA cohort with obstructive sleep apnea with and without daytime sleepiness (oral presentation). *Swedish Sleep Medicine Congress, 2010, Gothenburg.*
  14. Thunström E, Glantz H, Cederin B, Kallryd A, Ejdebäck J, Herlitz J, **Peker Y**. Baseline characteristics of the revascularized patients with coronary artery disease and obstructive sleep apnea in the RICCADSA trial (oral presentation). *Swedish Sleep Medicine Congress, 2010, Gothenburg.*
  15. Celen YT, Glantz H, Sengören Ö, Thunström E, Than T, Ejdebäck J, **Peker Y**. Adherence to CPAP treatment in patients with coronary artery disease and obstructive sleep apnoea without sleepiness: a preliminary report from the RICCADSA trial (poster). *European Respiratory Society Congress, Sept 12-16, 2009, Vienna, Austria. Eur Respir J 2009, Vol 34, Suppl 53, p.653-654s.*
  16. Glantz H, Celen YT, Thunström E, Kallryd A, Ejdebäck J, **Peker Y**. Följsamhet vid CPAP behandling hos kranskärlssjuka med sömnapné utan dagtidssömnighet: En preliminär rapport från RICCADSA studien (In Swedish) (*the best poster award*) *Sv Läk, Riksst., 2009, Stockholm.*
  17. Glantz H, Celen YT, Thunström E, Cederin B, Kallryd A, Ejdebäck J, Herlitz J, **Peker Y**. Adherence to CPAP treatment in patients with coronary artery disease and obstructive sleep apnoea without sleepiness: a preliminary report from the RICCADSA trial (oral presentation). *Swedish Sleep Medicine Congress, 2009, Uppsala.*



18. **Peker Y**, Glantz H, Thunström E, Kallryd A, Herlitz J, Ejdebäck J. RICCADSA: Randomized Intervention with CPAP in Coronary Artery Disease and Obstructive Sleep Apnea (poster). *American Thoracic Society Congress, May 16-21, 2008, Toronto, Canada. Am J Respir Crit Care Med* 2008, Vol 177 (part 2 of 2), A480.
19. Glantz H, Thunström E, Kallryd A, Ejdebäck J, Herlitz J, **Peker Y**. Hög förekomst av sömnapné hos revasculariserade kranskärlsjuka - RICCADSA studien (in Swedish) (poster). *Sv Läk, Riksst.*, 2008, Gothenburg.
20. Glantz H, Thunström E, Kallryd A, Ejdebäck J, Herlitz J, **Peker Y**. High prevalence of obstructive sleep apnea in revascularized patients with coronary artery disease (oral presentation). *Swedish Sleep Medicine Congress, 2008, Skövde.*
21. Glantz H, Thunström E, Kallryd A, Ejdebäck J, Herlitz J, **Peker Y**. High prevalence of obstructive sleep apnea in revascularized patients with coronary artery disease (oral presentation). *Swedish Sleep Medicine Congress, 2008, Skövde.*
22. **Peker Y**, Glantz H, Thunström E, Kallryd A, Herlitz J, Ejdebäck J. High prevalence of obstructive sleep apnoea in revascularized patients with coronary artery disease -RICCADSA trial (oral presentation). *European Respiratory Society Congress, Oct 4-8, 2008, Berlin, Germany. Eur Respir J* 2008, Vol 32, Suppl 52, p.130s.
23. **Peker Y**, Glantz H, Thunström E, Kallryd A, Herlitz J, Ejdebäck J. Rationale and design of the randomized intervention with CPAP in coronary artery disease and obstructive sleep apnoea -RICCADSA trial (poster). *European Respiratory Society Congress, Sept 15-19, 2007, Stockholm, Sweden. Eur Respir J* 2007, Vol 30, Suppl 51, p.509s.
24. **Peker Y**, Grote L, Johannsson G, Hedner J. Impact of CPAP treatment on sympathetic activity and renin-angiotensin-aldosterone system in normotensive men with obstructive sleep apnoea (oral presentation). *ERS Congress, Copenhagen, Denmark. The European Respiratory Journal, 2006; 28 (Suppl.50),294s.*
25. **Peker Y**, Svensson J, Grote L, Hedner J, Johannsson G. Sleep apnea and quality of life in growth hormone deficient adults before and six months following growth hormone therapy (poster). *ERS Congress, Copenhagen, Denmark. The European Respiratory Journal, 2005; 26 (Suppl.49),570s.*
26. Hedner J, Kraiczi H, **Peker Y**, Grote L. Reduction of sleep apnea after the orally available cholinesterase inhibitor donepezil (poster). *World Association of Sleep Medicine (WASM) Congress, Berlin, Germany. Sleep Medicine, 2005; 6 (Suppl.2),s54-55.*
27. Ding Z, Grote L, **Peker Y**, Bar A, Lindblad U, Hedner J. A portable monitoring device for sleep apnea diagnosis- a new validation standard using in a population based cohort? (poster). *World Association of Sleep Medicine (WASM) Congress, Berlin, Germany. Sleep Medicine, 2005; 6 (Suppl.2),s100-101.*
28. **Peker Y**, Carlson J, Hedner H. Förhöjd incidens av kranskärlssjukdom och kardiovaskulär mortalitet hos tidigare hjärtfriska sömnapnoiker: En 7-årsuppföljning. (in Swedish) (best abstract award). *Svenskt kardiovaskulärt vårmöte, Göteborg, 2004; p.6.*
29. **Peker Y**, Hedner J, Bengtsson K, Grote L, Råstam L, Lindblad U. Health related quality of life in hypertension and obstructive sleep apnoea: a community-based study (poster). *ERS Congress, Glasgow, UK. The European Respiratory Journal, 2004; 24 (Suppl.48),329s.*
30. Hedner J, Kraiczi H, Murphy P, **Peker Y**. Reduction of sleep disordered breathing by physostigmine (oral presentation). *ERS Congress, Vienna, Austria. The European Respiratory Journal, 2003; 22 (Suppl.45),354s.*

31. Torvaldsson S, Grote L, **Peker Y**, Hedner J. A comparison of two different autotitrating CPAP devices and constant CPAP in patients with obstructive sleep apnea (poster). *ATS Congress, Seattle, Washington. American Journal of Respiratory and Critical Care Medicine, 2003; 167 (Part 2 of 2), A327.*
32. **Peker Y**, Hedner J, Bengtsson K, Grote L, Råstam L, Lindblad U. Epworth Sleepiness Scale does not predict sleep-disordered breathing in a community-based population (poster). *APSS Congress, Chicago, Illinois. SLEEP, 2003; 26 (Suppl.), A271.*
33. **Peker Y**, Grote L, Johannsson G, Hedner J. The state and responsiveness of the renin-angiotensin-aldosterone system in obstructive sleep apnoea (poster). *ERS Congress, Vienna, Austria. The European Respiratory Journal, 2003; 22 (Suppl.45), 90s.*
34. Ding Z, Grote L, Derek NE, **Peker Y**, Hedner J. Blood pressure and apnea induced skin circulatory response after two antihypertensive agents in OSA patients (poster). *ERS Congress, Vienna, Austria. The European Respiratory Journal, 2003; 22 (Suppl.45), 94s.*
35. Torvaldsson S, Grote L, **Peker Y**, Hedner J. A comparison of two different autotitrating CPAP devices and constant CPAP in patients with obstructive sleep apnea (poster). *ERS Congress, Vienna, Austria. The European Respiratory Journal, 2003; 22 (Suppl.45), 94s.*
36. **Peker Y**, Norum J, Carlson J, Hedner J. Increased cardiovascular mortality in obstructive sleep apnoea: a seven-year follow-up (poster). *ATS Congress, Atlanta, Georgia. American Journal of Respiratory and Critical Care Medicine, 2002; 165 (Part 2 of 2), A232.*
37. **Peker Y**, Norum J, Carlson J, Hedner J. Increased incidence of coronary artery disease in obstructive sleep apnoea: a seven-year follow-up (poster). *ATS Congress, Atlanta, Georgia. American Journal of Respiratory and Critical Care Medicine, 2002; 165 (Part 2 of 2), A511.*
38. Hedner J, Kraiczi H, Murphy P, **Peker Y**. Reduction of sleep disordered breathing after physostigmine (poster). *ATS Congress, Atlanta, Georgia. American Journal of Respiratory and Critical Care Medicine, 2002; 165 (Part 2 of 2), A725.*
39. Torvaldsson S, Grote L, Basun H, **Peker Y**, Hedner J. Lack of effect of an N-Methyl-D-Aspartate antagonist in obstructive sleep apnea (poster). *ATS Congress, Atlanta, Georgia. American Journal of Respiratory and Critical Care Medicine, 2002; 165 (Part 2 of 2), A724.*
40. **Peker Y**, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea (poster). *ATS Congress, San Francisco, California. American Journal of Respiratory and Critical Care Medicine, 2001; 163 (Part 2 of 2), A631.*
41. **Peker Y**, Norum J, Hedner J, Carlson J. Increased cardiovascular mortality in obstructive sleep apnoea: a seven-year follow-up (poster). *ERS Congress, Berlin, Germany. The European Respiratory Journal, 2001; 16 (Suppl. 33), 343s.*
42. **Peker Y**, Norum J, Hedner J, Carlson J. Increased incidence of coronary artery disease in obstructive sleep apnoea: a seven-year follow-up (poster). *ERS Congress, Berlin, Germany. The European Respiratory Journal, 2001; 16 (Suppl. 33), 518s.*
43. **Peker Y**, Hedner J, Kraiczi H, Carlson J. Reduction of the elevated vasoconstrictor response to angiotensin-II in obstructive sleep apnoea (poster). *ERS Congress, Florence, Italy. The European Respiratory Journal, 2000; 16 (Suppl. 31), 335s.*
44. **Peker Y**, Hedner J, Sun XY, Zhao XH, Kraiczi H, Kjellström, C, der Sarkissian S, Marchand E, deBlois D, Hamet P. Early apoptosis in myocardium of rats exposed to repeated intermittent hypoxia: A pilot study. ( oral presentation). *ATS Congress, Toronto, Canada. American Journal of Respiratory and Critical Care Medicine, 2000; 161 (Part 2 of 2), A213.*

45. **Peker Y**, Hedner J, Kraiczi H, Löth S. Increased risk of mortality in patients with coronary artery disease and concomitant obstructive sleep apnea: A five-year follow-up (poster). *ATS Congress, San Diego. American Journal of Respiratory and Critical Care Medicine, 1999; 159 (Part 2 of 2).*
46. **Peker Y**, Hedner J, Kraiczi H, Löth S. Respiratory Disturbance Index as an independent predictor of cardiovascular mortality in coronary artery disease: A prospective study (oral presentation). *ERS Congress, Madrid, Spain. The European Respiratory Journal, 1999; 14 (Suppl. 30), 269s.*
47. **Peker Y**, Kraiczi H, Hedner J, Löth S. Morbidity and mortality in patients with obstructive sleep apnea and coronary heart disease: A three year follow-up study (poster). *ATS Congress, Chicago. American Journal of Respiratory and Critical Care Medicine, 1998; 157 (Part 2 of 2), A 62.*
48. **Peker Y**, Kraiczi H, Hedner J, Löth S. Increased risk of myocardial infarction and cardiovascular mortality in patients with coronary heart disease and concomitant obstructive sleep apnoea (oral presentation). *14<sup>th</sup> Congress of the European Sleep Research Society, Madrid, Spain. Journal of Sleep Research, 1998; (7, Suppl. 2), 203s.*
49. **Peker Y**, Hedner J, Kjellström C, Sun XY, Zhao XH, Kraiczi K. Apoptosis in the heart of rats exposed to repeated intermittent hypoxia: A potential pathogenetic cardiovascular mechanism in obstructive sleep apnoea? ( oral presentation). *ERS Congress, Geneva, Swiss. The European Respiratory Journal, 1998; 12 (Suppl. 28), 257s.*
50. **Peker Y**, Hedner J, Johansson Å, Bende M. Reduced hospitalization with cardiovascular and pulmonary disease in obstructive sleep apnea patients on nasal CPAP treatment (poster). *ATS Congress, San Fransisco. American Journal of Respiratory and Critical Care Medicine, 1997; 155 (4, Part 2 of 2) A 845.*
51. **Peker Y**, Hedner J, Johansson Å, Bende M. Cost utility of long-term nasal CPAP treatment in obstructive sleep apnea syndrome with cardiovascular and pulmonary disease (poster). *5<sup>th</sup> World Congress on Sleep Apnea, Marburg, Germany, 1997.*
52. **Peker Y**, Kraiczi H, Hedner J, Löth S, Bende M, Johansson Å. Obstruktiv sömnapné: Oberoende riskfaktor för kranskärlssjukdom (in Swedish). *Sv Läk. Riksst, 1997.*
53. **Peker Y**, Kraiczi H, Hedner J, Löth S, Bende M, Johansson Å. Obstructive sleep apnea- a risk factor for coronary heart disease (oral presentation). *ERS Congress, Berlin, Germany. The European Respiratory Journal, 1997; 10 (Suppl. 25), 13s.*
54. **Peker Y**, Bende M, Johansson Å. The need for hospital treatment for cardiovascular or pulmonary disease before and after CPAP-treatment of sleep apnea (oral presentation). *5<sup>th</sup> Scandinavian Sleep Research Congress, Uppsala, 1995.*
55. **Peker Y**, Bende M, Johansson Å, Löth S. Prevalence of sleep apnea syndrome in a cardiac intensive-care unit (oral presentation). *5<sup>th</sup> Scandinavian Sleep Research Congress, Uppsala, Sweden 1995.*
56. **Peker Y**, Bende M, Johansson Å. Slutenvårdskonsumtion hos sömnapnoiker med hjärt-kärl- eller lungsjukdom före och efter CPAP behandling (poster) (in Swedish). *Sv Läk. Riksst, 1995, p 228.*
57. **Peker Y**, Johansson Å. Symtomlindring och minskad vårdkonsumtion efter CPAP behandling hos sömnapnoiker (poster) (in Swedish). *Sv Läk. Riksst, 1993, p 231.*

#### 4. Other publications

1. **Peker Y.** Ph D Thesis: Obstructive sleep apnea and cardiovascular morbidity. Gothenburg University, 2000.
2. **Peker Y.** Unburdening the heart. *Pan European Networks: Science and Technology*. 2014.
3. **Peker Y.** Breathing easy. *International Innovation*. November 2012.
4. **Peker Y.** Kliniska karaktäristika av revaskulariserade kranskärlssjuka I RICCADSA studien: Sömnapné vanligare än obesitas, rökning, diabetes och hypertoni (in Swedish). *Lung & Allergi Forum* 2011;1:26-29.

---

### PROFESSIONAL ACTIVITIES

#### TEACHING:

- Courses and lectures for the medical school students at the Medical Faculty of the University of Gothenburg 1998-2002, at Skaraborg Hospital, Skövde, Sweden, 2002-2014, at the Medical Faculty of Marmara University, Istanbul, 2015-ongoing.
- Tutor for 18 international guest researchers, mainly from Turkey, at the Skaraborg Hospital, Skövde, Sweden in periods, during 2007-2014.
- Main tutor for PhD students in Sweden:
  - Erik Thunström, MD (PhD student 2007-2015; defended thesis in November 2015).
    - Obstructive Sleep Apnea and Cardiovascular Disease: Mechanisms and Impact of Treatment
  - Helena Glantz, MD (PhD student 2007-2016; defended PhD thesis in March 2016).
    - Obstructive Sleep Apnea in Coronary Artery Disease: Impact of CPAP.
- Main tutor for MD in Turkey:
  - Tugce Yakut, MD (defended specialty thesis in November 2016).
    - Prevalence of Obstructive Sleep Apnea and Pulmonary Involvement in Patients with Scleroderma

#### RESEARCH:

1.

Grant Number	Grant Title	Role in Project	Years Inclusive	Source \$ Amount
--------------	-------------	-----------------	-----------------	------------------

#### **Current Grant Support:**

*Cardiovascular mechanisms, adherence and impact of CPAP in coronary artery disease and nonsleepy obstructive sleep apnea: A randomized, controlled trial*

521-2013-3439. The Swedish Research Council. Principal Investigator. 2015-2017.

2.100.000 SEK (233.847 \$)

*Obstructive sleep apnea and cardiovascular morbidity: prevalence, phenotypes, pathophysiological mechanisms and impact of treatment*

ALFGBG-150801. ALF Västra Götalandsregionen. Principal Investigator. 2015-2017.

1.575.000 SEK (175.386 \$)

#### **Prior Grant Support:**

*The RICCADSA Trial.*

521-2013-3439. The Swedish Research Council. 2011-2012. 1.800.000 SEK (200.441 \$)

*Sleep apnea and coronary artery disease.*

20110469. The Swedish Heart and Lung Foundation. 2012. 300.000 SEK (33.407 \$)  
20100664. The Swedish Heart and Lung Foundation. 2011. 200.000 SEK (22.271 \$)  
20090708. The Swedish Heart and Lung Foundation. 2010. 200.000 SEK (22.271 \$)  
20080592. The Swedish Heart and Lung Foundation. 2009. 200.000 SEK (22.271 \$)  
20060552. The Swedish Heart and Lung Foundation. 2007-2008. 500.000 SEK (55.678 \$)

*The RICCADSA trial*

ResMed Foundation. 2011-2012 150.000 \$  
ResMed Foundation. 2009-2010 100.000 \$  
ResMed Ltd 2008 80.000 \$  
ResMed Ltd 2006 600.000 SEK (66.814 \$)

*Obstructive sleep apnea and cardiovascular morbidity: impact of CPAP treatment*

ALFGBG-11538. ALF Västra Götaland. 2008-2010. 861.000 SEK (95.978 \$)

*The RICCADSA trial*

The Research Fund at Skaraborg Hospital. 2010. 190.000 SEK (21.157 \$)  
The Research Fund at Skaraborg Hospital. 2009. 350.000 SEK (38.975 \$)  
The Research Fund at Skaraborg Hospital. 2008. 200.000 SEK (22.271 \$)  
The Research Fund at Skaraborg Hospital. 2007. 260.000 SEK (28.953 \$)  
The Research Fund at Skaraborg Hospital. 2006. 400.000 SEK (44.542 \$)  
The Research Fund at Skaraborg Hospital. 2005. 300.000 SEK (33.407 \$)

*The RICCADSA trial*

The Heart Foundation of Kaernsjukhuset. 2010. 250.000 SEK (27.839 \$)  
The Heart Foundation of Kaernsjukhuset. 2009. 200.000 SEK (22.271 \$)  
The Heart Foundation of Kaernsjukhuset. 2008. 300.000 SEK (33.407 \$)  
The Heart Foundation of Kaernsjukhuset. 2006. 250.000 SEK (27.839 \$)  
The Heart Foundation of Kaernsjukhuset. 2005. 250.000 SEK (27.839 \$)

*The LosartanPAP Trial*

The Skaraborg Research and Development Council. 2009. 110.000 SEK (12.250 \$)

*Sleep Apnea Patients in Skaraborg*

The Research Fund at Skaraborg Hospital. 2014. 240.000 SEK (26.725 \$)

*Postdoc Fellowship Grants*

The Swedish Heart and Lung Foundation. 2002. 732.000 SEK (81.513 \$)  
The University of Gothenburg. 2001. 240.000 SEK (26.725 \$)

*Multicenter Drug/ASV Studies*

ServeHF. Gothenburg. ResMed. 2014. 80.000 SEK (8.900 \$)  
Bioprojet Pharma. OSA. Hypersomnolence. 2012. 400.000 SEK (44.542 \$)

Pfizer. RLS.	2010.	700.000 SEK (77.949 \$)
Actelion. Insomnia.	2007.	250.000 SEK (27.839 \$)
Boehringer Ingelheim. RLS.	2006.	500.000 SEK (55.678 \$)

## **2. Seminars and invited lectureships related to your research**

### *INVITED LECTURER – NATIONAL & INTERNATIONAL MEETINGS*

1. 2016 (17 November). French Sleep Research Society Meeting, Strasbourg, France. “Impact of PAP treatment in coronary artery disease and nonsleepy obstructive sleep apnea in the RICCADSA trial”.
2. 2016 (3 September). European Respiratory Society Meeting. London, England. Postgraduate Course. “Sleep Apnoea and Coronary Artery Disease”.
3. 2016 (27 May). Turkish Sleep Society Meeting, Trabzon, Turkey. “The new driver-license legislation for sleep apnea patients”.
4. 2016. (30 April). CardioSleep Meeting, Prague, Czech Republic. “Rationale for & Update on ISAACC and RICCADSA Trials”.
5. 2016. (8 April). French Pulmonology Meeting, Izmir, Turkey. “Is sleep apnea responsible for coronary artery disease?”
6. 2016. (7 April). Turkish Thoracic Society Meeting, Antalya, Turkey. “Treatment of OSA in Coronary Artery Disease”
7. 2016. (16 March). Turkish National Lung Health Congress, Antalya, Turkey. “Treatment of OSA – General principles”
8. 2015. (7 May). Nordic Sleep Meeting, Gothenburg, Sweden. “Recent challenges in cardiovascular sleep research”
9. 2015. (11 April). CardioSleep Meeting, Paris, France. “Coronary heart disease & sleep apnea: Results from the RICCADSA trial.”
10. 2014. (3 November). Turkish Sleep Medicine Society, Antalya, Turkey. Symposium. “Treatment approaches in obstructive sleep apnea”
11. 2013. (10 September). ResMed Nordic. ERS meeting, Barcelona. Symposium. “Coronary artery disease and obstructive sleep apnea: the first results from the RICCADSA trial”.
12. 2013. (3-7 April). Turkish Thoracic Society. Symposium. “National differences in the management of obstructive sleep apnea in the world”
13. 2013. (30 March). Memorial Hospital, Istanbul, Turkey. Lecture. “Heart & Sleep”.
14. 2012. (15 December). Turkish Sleep Medicine Society, Antalya, Turkey. Symposium. “Hemodynamic changes and cardiovascular risk in obstructive sleep apnea”.
15. 2012. (11 December). Süleyman Demirel University, Isparta, Turkey. Lectures. 1) Metabolic and cardiovascular comorbidities in obstructive sleep apnea; 2) Impact of CPAP in coronary artery disease and obstructive sleep apnea; 3) An update of management of obstructive sleep apnea.
16. 2012. (4 October). Stroke Team Congress, Gothenburg, Sweden. Symposium. “Stroke and sleep apnea”
17. 2012. (28-29 June) Sleep and Aging 2012, Paris, France. Symposia. 1) Coronary artery disease and OSAS: Effects of CPAP – the RICCADSA trial; 2) Mechanisms of cardiovascular consequences in OSAS.

18. 2012. (18-20 April). Society for Cardiothoracic Surgery in Great Britain and Ireland, Manchester, England. Symposium. "Sleep apnoea and coronary artery disease: population and clinic-based epidemiology".
19. 2012. (2 March). Turkish Ear-Nose-Throat Society, Bursa, Turkey, Symposia. 1) Obstructive sleep apnea syndrome; 2) Cardiovascular complications of obstructive sleep apnea.
20. 2011. (24 August). ResMed Meeting, Oslo, Norway. "Obstructive sleep apnea & coronary disease: Impact of CPAP treatment".
21. 2011. (21-25 October) Turkish Sleep Medicine Society, Bodrum. Turkey. Lectures and symposia: 1) What is the level of evidence of the relationship between obstructive sleep apnea and cardiovascular and metabolic diseases? 2) Impact of CPAP treatment on diabetes, hypertension and coronary artery disease; 3) Cardiovascular consequences of untreated sleep apnea.
22. 2011. (24 May) European Cardiology Society & Heart Failure 2011, Gothenburg, Sweden. Symposium. "Sleep apnea - the need to synchronize the heart, the lung and the brain" – Future possibilities in treatment of sleep apnea.
23. 2011. (4 May). Pulmonologists in Stockholm, Sweden. "Sleep apnea – Lessons from the RICCADSA study" (Sponsored by Boehringer Ingelheim).
24. 2011. (6 January) Erciyes University, Kayseri, Turkey. Guest Associate Professor Lecture: Sleep apnea and cardiovascular morbidity.
25. 2010. Turkish Sleep Medicine Society, Antalya, Turkey. 1) Postgraduate Course. Evaluation of cardiac parameters in polysomnography; 2) Cardiovascular consequences of sleep apnea.
26. 2010. Sleep and Aging 2010, Lyon, France. Symposia 1) Coronary artery disease, stroke and sleep apnea in the elderly. 2) Impact of antihypertensive drugs in OSAS patients: update 2010.
27. 2010. Turkish Thoracic Society, Istanbul, Turkey. Symposium. Cardiovascular complications of sleep apnea.
28. 2010. Turkish Sleep Medicine Society & Japanese Sleep Medicine Society, Izmir, Turkey. Symposium. Cardiac findings and sleep.
29. 2010. Bursa University, Thorax Symposium, Bursa, Turkey. Cardiovascular mechanisms and impact of CPAP treatment in sleep apnea.
30. 2009. Pittsburgh University Hospital, Pittsburgh. Lecture. Sleep Apnea and Coronary Artery Disease.
31. 2009. Turkish Sleep Medicine Society, Antalya. Turkey. 1) Postgraduate Course. Evaluation of cardiac parameters in polysomnography; 2) Insomnia in COPD; 3) Diagnostic approach to sleep disorders in cardiac patients.
32. 2009. Turkish Thoracic Society, Istanbul, Turkey. Symposium. 1) The effect of PAP treatment on metabolic syndrome; 2) Heart in sleep-related breathing disorders.
33. 2009. Hackensack University Hospital, New Jersey. Lecture. Sleep Apnea and Cardiovascular Morbidity.
34. 2009. European Cardiology Society & Heart failure 2009. Satellite symposium. Should we screen cardiac patients for sleep apnea? - Sleep apnea and ischemic heart disease. Nice, France.
35. 2009. Turkish Thoracic Society, Antalya, Turkey. 1) Pro-Con debate. Polysomnography is always necessary in diagnosis of sleep apnea (*Yes*: Sadik Ardic; *No*: Yüksel Peker); 2) Hot topic. Central Sleep Apnea.

36. 2009. Turkish Thoracic Society, Eskisehir, Turkey. Necla Özdemir Symposium. Obstructive sleep apnea and cardiovascular morbidity.
37. 2008. Turkish Sleep Medicine Society, Kusadasi, Turkey. 1) Postgraduate course. Cardiac scoring in polysomnography; 2) Panel discussion. Problems in the management of sleep apnea: Cardiologic aspects; 3) Symposium. Hypertension and sleep-related breathing disorder.
38. 2008. American Thoracic Society, Toronto, Canada. Postgraduate Course. Ischemic Heart Disease and Sleep-Disordered Breathing.
39. 2008. Turkish Thoracic Society, Antalya, Turkey. 1) Symposium. Complications of sleep apnea; 2) Symposium. Sleep apnea and hypertension; 3) Clinical year in Review.
40. 2007. Turkish Sleep Medicine Society, Bodrum, Turkey. 1) Postgraduate course. Cardiac scoring in polysomnography; 2) Symposium. Obesity and sleep apnea; 3) Symposium Recent update regarding sleep apnea research.
41. 2007. European Respiratory Society (ERS), Stockholm, Sweden. Symposium. Gender-related differences in cardiovascular morbidity and mortality of sleep apnoea patients.
42. 2006. Turkish Thoracic Society, Antalya, Turkey. 1) Symposium. Treatment of central sleep apnea syndrome. 2) Pro-Con debate. Should we treat all obstructive sleep apnea patients? (*Yes*: Yüksel Peker; *No*: Patrick Strollo, USA).
43. 2005. Respiratory Society of Bosnia, Sarajevo, Bosnia. Obstructive sleep apnea: an overview.
44. 2004. Turkish Thoracic Society, Antalya, Turkey. 1) Postgraduate Course. Cardiovascular aspects in practical polysomnography. 2) Symposium. Cardiovascular complications of obstructive sleep apnea.
45. 2003. Turkish Thoracic Society, Antalya, Turkey. 1) Pro-Con debate. Polysomnography is always necessary in diagnosis of sleep apnea (*Yes*: Christian Guilleminault, USA; *No*: Yüksel Peker); 2) Symposium. Sleep apnea and cardiovascular complications.
46. 2003. World Congress of Sleep Apnea, Helsinki, Finland. Satellite symposium. The impact of OSA treatment in cardiovascular mortality.
47. 2003. European Respiratory Society (ERS), Vienna, Austria. Symposium. Cardiovascular consequences of sleep apnea.
48. 2002. Turkish Thoracic Society, Antalya, Turkey. Postgraduate Course. Cardiac scoring in practical polysomnography.
49. 2002. Scandinavian Meeting on Sleep Apnea, Århus, Denmark. Cardiovascular complications of sleep apnea.
50. 2002. Turkish Sleep Research Society, Kayseri, Turkey. Cardiovascular morbidity in sleep apnea.
51. 2001. Bosnian Medical Association, Sarajevo, Bosnia. Key lecturer. Cardiovascular morbidity in sleep apnea.
52. 1999. Turkish Pulmonary Society, Istanbul, Turkey. Postgraduate Course. Sleep apnea & Cardiovascular complications.

### **3. Other research related activities.**

#### *ASSOCIATE EDITOR*

Annals of the American Thoracic Society (from 2017-March 15)



**EDITORIAL BOARD MEMBER**

American Journal of Respiratory and Critical Care Medicine (2013-ongoing)

**SCIENTIFIC JOURNAL REFEREE**

Nature Reviews Cardiology

JAMA

American Journal of Respiratory and Critical Care Medicine

Annals of American Thoracic Society

Lancet Respiratory Journal

European Respiratory Journal

Respiratory Medicine

Respiratory Research

Journal SLEEP

Journal of Clinical Sleep Medicine

Sleep Medicine

Journal of Sleep Research

Sleep Medicine Reviews

European Heart Journal

Heart

American Journal of Cardiovascular Drugs

European Journal of Endocrinology

Psychoneuroendocrinology

The Scandinavian Journal of Clinical & Laboratory Investigation

Tuberculosis and Thorax (Turkish/English)

The Anatolian Journal of Cardiology (Turkish/English)

**LIST of CURRENT RESEARCH INTERESTS:**

Sleep Medicine

Cardiovascular Aspects of Sleep Apnea

**SERVICE:**

**1. University and Medical School.**

Chairman of the Research Supporting Committee of the Medical Faculty of Marmara University,  
Istanbul, Turkey. 2015-ongoing

**2. Community activities.**

- *Include hospital appointments and consultantships*

April 2015-Ongoing Consultant Pulmonologist at the Marmara University Hospital,  
Istanbul, Turkey.

2004-2015 Consultant at the Sleep Medicine & Internal Medicine & Pulmonary  
Medicine, Skaraborg Hospital, Skövde, Sweden.

2003 Consultant Int. Med (50%), Skaraborg Hospital, Skövde.

1998-2002	Consultant Pulmonologist, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg. (part-time 2001-2002).
1996-1998	Clinical Practice (Training for Pulmonary Medicine including Thorax Radiology), Sahlgrenska University Hospital, Gothenburg.
1996	Clinical Practice at the Sleep Laboratory, Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg.
1996	Consultant in Int. Med, Skaraborg Hospital, Skövde, Sweden
1991-1996	Clinical Practice (Internship and Training for Internal Medicine) Skaraborg Hospital, Skövde.
1989-1991	Clinical Practice (Recidency), Int. Med., General Surgery, Psychiatry and General Practice, Skaraborg Hospital, Skövde.
1989	Clinical Practice, Östermalm Geriatrics Hospital, Skövde
1987-1988	Married, moved to Sweden (sept 1987), studied Swedish and completed the required language and medical examinations in order to be qualified as a medical doctor in Sweden.
1985-1987	General Practitioner in Sivas, Turkey (until Sept 1987).